CBIZ Investment Advisory Services LLC Buys 68 Shares of Eli Lilly and Company $LLY

CBIZ Investment Advisory Services LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.2% during the first quarter, Holdings Channel.com reports. The firm owned 548 shares of the company’s stock after purchasing an additional 68 shares during the quarter. CBIZ Investment Advisory Services LLC’s holdings in Eli Lilly and Company were worth $453,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in LLY. Duquesne Family Office LLC raised its stake in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the last quarter. Corient IA LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at about $570,000. LS Investment Advisors LLC raised its stake in Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after buying an additional 40 shares during the last quarter. Cutter Capital Management LP purchased a new stake in Eli Lilly and Company in the first quarter valued at about $14,866,000. Finally, Prism Advisors Inc. purchased a new stake in Eli Lilly and Company in the first quarter valued at about $207,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.2%

Shares of NYSE:LLY opened at $755.85 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $942.35. The stock has a market cap of $715.38 billion, a price-to-earnings ratio of 49.40, a PEG ratio of 1.05 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a 50-day moving average price of $741.52 and a 200-day moving average price of $778.38.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business posted $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $950.17.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.